As studies grow in size and complexity, sample preparation has become one of the key bottlenecks – impacting reproducibility, throughput, and scalability. To better understand how teams are navigating this, we asked the proteomics community across academia, pharma, clinical labs, and technology providers.
Biomarker tests have become an important tool in clinical diagnostics. The PSA test evaluates the risk for prostate cancer, and inflammatory and myocardial panels save lives when performed fast enough. Still biomarkers, especially protein biomarkers, are not yet used to their full potential. While novel approaches employ mass spectrometry instead of immunoassay detection, one bottleneck remains: the need for robust, fast, and efficient sample preparation.
